NCT06413667 Assessment of the Alignment of the Atlas and Surrounding Tissues in Chronic Whiplash Associated Disorder
| NCT ID | NCT06413667 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Condition | Chronic Whiplash Associated Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-04-08 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2024-04-08 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Whiplash is an injury caused by the rapid forward and backward movement of the neck, leading to injuries in bones or soft tissues, along with various symptoms. Recent studies indicate that muscles affected by whiplash may show increased fat buildup and reduced muscle volume. However, these changes in muscle do not completely account for the pain and other symptoms reported. Besides soft tissues, whiplash can also injure bone structures, including the cervical spine. Until now, studies focused mainly on fractures of the cervical spine, often overlooking the position and alignment of the atlas and dens (C1 and C2). The aim of this study is to evaluate the position and alignment of the Atlas in chronic whiplash-associated disorder (grades 1 or 2) and compare it to patients with tension headache and healthy controls. Additionally, it will explore how these factors relate to pain intensity, neck movement limitations, daily activities, overall improvement, and quality of life.
Eligibility Criteria
Inclusion Criteria: Participants fulfilling the criteria mentioned below: Control participants In order to be eligible to participate in this study, a participant must meet the following criteria: * Healthy individuals * Ability to follow test instructions * Aged between 18 - 75 years Chronic Whiplash Associated Disorder In order to be eligible to participate in this study, a participant must meet the following criteria: * Healthy individuals * Ability to follow test instructions * WAD 1 or 2 Diagnosis * Aged between 18 - 75 years Tension headache In order to be eligible to participate in this study, a participant must meet the following criteria: * Healthy individuals * Ability to follow test instructions * Diagnosis Tension headache * Aged between 18 -75 years Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: * Inability to provide informed consent * Have a history of claustrophobia * Patient/ participant is not eligible to follow instructions * Contra-indication for MRI (e.g., pacemaker, claustrophobia) * Being under investigation for non-diagnosed disease at the time of investigation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06413667 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Chronic Whiplash Associated Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06413667 currently recruiting?
Yes, NCT06413667 is actively recruiting participants. Contact the research team at a.j.nederveen@amsterdamumc.nl for enrollment information.
Where is the NCT06413667 trial being conducted?
This trial is being conducted at Amsterdam, Netherlands.
Who is sponsoring the NCT06413667 clinical trial?
NCT06413667 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). The trial plans to enroll 90 participants.